Polsinelli is pleased to announce that Hatch-Waxman & Biologics Practice Chair Chad A. Landmon and Shareholder Steve Stranne have been recognized in the 2025 LMG Life Sciences U.S. Lawyer Rankings.

Landmon is a first chair trial lawyer known for his adept handling of patent litigation, the Food and Drug Administration (FDA) approval processes and Administrative Procedure Act (APA) litigation, ensuring clients can efficiently and profitably bring their products to market. Beyond his primary focus, Landmon manages cases involving the cross-section of antitrust and patent law, particularly those arising from settlements of patent disputes and Hatch-Waxman Act exclusivity disputes. 

Stranne is a physician and lawyer with over 30 years of experience in problem-solving and executing strategies relating to reimbursement, coverage, coding, health care policy and patient access issues for medical device companies, life sciences companies, health care professional societies, health care provider systems and groups, start-ups and patient advocacy organizations. He is particularly effective in presenting complex clinical and scientific issues to policymakers, including advocacy before medical professionals and other decision makers within federal and state agencies. 

The LMG Life Sciences U.S. Firm & Lawyer Rankings highlight leading law firms and attorneys across the life sciences sector, based on casework evidence and extensive client and peer interviews.

Polsinelli’s multidisciplinary Life Sciences Practice brings together attorneys, patent agents, scientists and professionals who understand the unique challenges faced by life sciences companies. The team provides comprehensive legal support at every stage of a company’s lifecycle, from formation through commercialization, offering counsel on corporate governance, licensing, mergers and acquisitions, venture capital, patent strategy, FDA compliance, litigation, employment, government incentives and real estate matters.